Shibeikang Biomedical

Company Profile

Company
Profile

Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world and dedicated to differentiated drug innovation. Guided by our mission of Empowering Better Health Through Inclusive Care and Support, SBK is committed to the core values of "People-centered, Driven by Change, Innovation at the Core". Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to becoming a world leader in the differentiated innovation of novel drugs - developing better medicines to patients and advancing human health.

Corporate Timeline

2025

On January 3rd EST, SBK submitted the FDA IND application for SBK002.
On March 6th, SBK013 tablets received clinical trial approval from the National Medical Products Administration (Approval No.: 2025LP00574).

2024

SBK launched its global strategic plan, with SBK002 completing FDA pre-IND communication and receiving full endorsement from the FDA.
SBK established its Beijing branch, officially commencing operations.
SBK's first R&D product, chloral hydrate syrup, was approved for market launch and included in the 2024 National Reimbursement Drug List.
SBK signed a strategic collaboration with the National Key Laboratory for Innovative Drug Discovery of Major Diseases to accelerate the transformation of innovative drug R&D.
The Phase 1 clinical trial for the Class 1 innovative drug SBK007 tablets was completed, meeting all clinical endpoints.
The clinical trial application for the Class 1 innovative drug SBK013 was accepted.

2023

SBK's independently developed and fully validated metabolic differentiation innovation platform has been established, laying a solid foundation for the company’s sustainable innovation strategy.
SBK's innovative drugs, including SBK007, SBK010, and SBK011, received clinical trial approvals.
SBK obtained its first "Drug Manufacturing License" (Type B) for its Class 1 innovative drug, SBK002 tablets.

2022

The Phase I clinical trial for the Class 1 innovative drug SBK001 injection was completed, successfully meeting all clinical endpoints.
In 2022, SBK closed its A+ funding round, securing tens of millions of RMB in additional investment from a leading Sichuan-based fund.

2021

SBK's next-generation Class 1 innovative drug, SBK001, targeting the respiratory system, received clinical approval and initiated clinical studies.
SBK's chloral hydrate syrup, a best-in-class exclusive product, gained Pre-NDA acceptance.
In September 2021, SBK attracted additional investment of tens of millions of RMB from a prestigious industrial investment institution and completed commercialization licensing deals exceeding RMB 100 million.

2020

SBK's first Class 1 innovative drug, SBK002, was approved for clinical trials.
SBK relocated to a new R&D facility, significantly expanding and enhancing its R&D system, marking the beginning of a rapid growth phase.

2019

SBK's first new drug received clinical acceptance from the National Medical Products Administration.

2017

After realigning its strategy to prioritize innovative drug R&D, SBK successfully discovered multiple novel compounds, with two projects named.

2015

Chengdu Shibeikang Biomedical Technology Co., Ltd. was established.

About Us

About Us